Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

By afschroeder • November 30, 2025

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster JD, Rieder N, Dietmann G, Cannarile M, Cotter C, Hack SP, Cha E, Ishiguro T, Llovet JM, Zhu AX, Finn RS. Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy. Cell Rep Med. 2025 Nov 28:102473. doi: 10.1016/j.xcrm.2025.102473. Epub ahead of print. PMID: 41317730.

Tags: Atezolizumab, Bevacizumab, HCC, Hematology/Oncology, immunotherapy, liver cell lineages, mechanisms of response and resistance, molecular subtype, Publications

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review

Smith CE, Sammons SL, Minami CA, Sedrak MS, Magnuson A, O'Connor T, Hshieh TT, Smith S, Ruderman K, Bak K, Lin NU, Freedman RA. Systemic[...]

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers

Shachar EK, Silverstein J, Gornbein J, Salani R, Karlan BY, Chase DM. Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related[...]

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]